@phdthesis{Arva2015,
  author    = {Arva, Ana-Lioara},
  title     = {Aktuelle Aspekte der pharmako-mechanischen Rekanalisation von Gef{\"a}ßverschl{\"u}ssen bei akutem Hirninfarkt},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-118417},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Fragestellung Die Prognose eines akuten Hirninfarktes bei Verschluss einer proximalen Hirnarterie ist trotz der intraven{\"o}sen Thrombolyse mit rtPA ung{\"u}nstig. Kann die kombinierte pharmaco-mechanische Rekanalisation von proximalen Gef{\"a}ßverschl{\"u}ssen bei akutem Hirninfarkt zu einer Verbesserung des klinischen Ergebnisses f{\"u}hren? Methoden Wir analysierten retrospektiv 66 konsekutiv aufgenommene Patienten (36m, 30w; mittleres Alter 61 Jahre (23-86 Jahre), die von 2010 bis 2012 kombiniert pharmako-mechanisch intra-arteriell behandelt wurden. 32 Patienten wiesen einen kombinierten ACI-/M1-Verschluss, 23 einen M1-Verschluss und 11 eine Basilaristhrombose auf. Mittlerer NIHSS lag bei 23. 57 Patienten erhielten eine kombinierte pharmaco-mechanische Therapie, 3 Patienten wurden lediglich pharmakologisch und 6 Patienten rein mechanisch rekanalisiert. Rekanalisierung bei 35 Patienten mit einem Stent-Retriever (32 Patienten mit pREset, 3 Patienten mit SOLITAIRE) erfolgt. Bei 46 Patienten wurde rtPA und bei 32 Patienten Tirofiban als Bridging Verfahren eingesetzt. Eine Stentanlage erfolgte in 28,78\% der F{\"a}lle. Ergebnisse Die erzielten Rekanalisationsraten lagen bei 89,4\% bei einer mittleren Dauer der Intervention von 96 Minuten (53,03\% unter 90 Min.). Ein g{\"u}nstiges klinisches Ergebnis nach mRS (mRS 0-2) wurde bei 48\% der Patienten erreicht. Die Rate an symptomatischen intrazerebralen Blutungen lag bei 4,55\%. Die Mortalit{\"a}t war 19,7\%. Die multivariate Regressionsanalyse ergab als modifizierbare Prediktoren f{\"u}r ein g{\"u}nstiges Outcome die Dauer bis zur Rekanalisation und die Gabe von rtPA. Schlussfolgerungen Die kombinierte endovaskul{\"a}re pharmako-mechanische Therapie kann die Mortalit{\"a}t und Morbidit{\"a}t von Schlaganfallpatienten mit Verschl{\"u}ssen einer proximalen Hirnarterie reduzieren.},
  subject      = {Hirninfarkt},
  language  = {de}
}
@article{LendersWeidemannKurschatetal.2016,
  author    = {Lenders, Malte and Weidemann, Frank and Kurschat, Christine and Canaan-K{\"u}hl, Sima and Duning, Thomas and Stypmann, J{\"o}rg and Schmitz, Boris and Reiermann, Stefanie and Kr{\"a}mer, Johannes and Blaschke, Daniela and Wanner, Christoph and Brand, Stefan-Martin and Brand, Eva},
  title     = {Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {11},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {54},
  doi       = {10.1186/s13023-016-0441-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166559},
  year      = {2016},
  abstract  = {Background Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma. Methods To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations. Results p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 \% of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed. Conclusions We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.},
  language  = {en}
}
@techreport{OPUS4-35963,
  title     = {Platelets - Molecular, cellular and systemic functions in health and disease},
  editor    = {Nieswandt, Bernhard},
  organization    = {Collaborative Research Centre/Transregio 240},
  doi       = {10.25972/OPUS-35963},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-359636},
  pages     = {25},
  year      = {2024},
  abstract  = {Besides their central role in haemostasis and thrombosis, platelets are increasingly recognised as versatile effector cells in inflammation, the innate and adaptive immune response, extracellular matrix reorganisation and fibrosis, maintenance of barrier and organ integrity, and host response to pathogens. These platelet functions, referred to as thrombo-inflammation and immunothrombosis, have gained major attention in the COVID-19 pandemic, where patients develop an inflammatory disease state with severe and life-threatening thromboembolic complications. In the CRC/TR 240, a highly interdisciplinary team of basic, translational and clinical scientists explored these emerging roles of platelets with the aim to develop novel treatment concepts for cardiovascular disorders and beyond. We have i) unravelled mechanisms leading to life-threatening thromboembolic complica-tions following vaccination against SARS-CoV-2 with adenoviral vector-based vaccines, ii) identified unrecognised functions of platelet receptors and their regulation, offering new potential targets for pharmacological intervention and iii) developed new methodology to study the biology of megakar-yocytes (MKs), the precursor cells of platelets in the bone marrow, which lay the foundation for the modulation of platelet biogenesis and function. The projects of the CRC/TR 240 built on the unique expertise of our research network and focussed on the following complementary fields: (A) Cell bi-ology of megakaryocytes and platelets and (B) Platelets as regulators and effectors in disease. To achieve this aim, we followed a comprehensive approach starting out from in vitro systems and animal models to clinical research with large prospective patient cohorts and data-/biobanking. Despite the comparably short funding period the CRC/TR 240 discovered basic new mechanisms of platelet biogenesis, signal transduction and effector function and identified potential MK/platelet-specific molecular targets for diagnosis and therapy of thrombotic, haemorrhagic and thrombo-inflammatory disease states.},
  subject      = {Thrombozyt},
  language  = {en}
}